RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
about
Emerging Functions of RANKL in Lymphoid TissuesOsteoprotegerin levels in patients with severe mental disordersRANK-RANKL signalling in cancerAnti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidencesUp-regulated expression of extracellular matrix remodeling genes in phagocytically challenged trabecular meshwork cellsOsteonecrosis of the jaw in a patient on Denosumab.Mild hypothermia in combination with minimally invasive evacuation of hematoma reduces inflammatory damage in patients via the nuclear factor-κB pathway.Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.Osteoprotegerin expressed by osteoclasts: an autoregulator of osteoclastogenesis.Genome-wide association study of gene by smoking interactions in coronary artery calcification.Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medicationsThe aortic ring model of angiogenesis: a quarter century of search and discovery.WSS25, a sulfated polysaccharide, inhibits RANKL-induced mouse osteoclast formation by blocking SMAD/ID1 signaling.Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial.Proteoglycans and osteolysisThe deep-sea natural products, biogenic polyphosphate (Bio-PolyP) and biogenic silica (Bio-Silica), as biomimetic scaffolds for bone tissue engineering: fabrication of a morphogenetically-active polymer.Pharmacological control of secondary hyperparathyroidism in chronic hemodialysis patients: cinacalcet is coming to Japan.Osteoprotegerin disrupts peripheral adhesive structures of osteoclasts by modulating Pyk2 and Src activities.Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary DiseaseRANKL/RANK/OPG: key therapeutic target in bone oncology.Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma.Toll gates to periodontal host modulation and vaccine therapyDysregulation of macrophage polarization is associated with the metastatic process in osteosarcoma.Transforming Growth Factor β1/Smad4 Signaling Affects Osteoclast Differentiation via Regulation of miR-155 Expression.Skeletal and extraskeletal actions of denosumab.The role of osteoprotegerin in cardiovascular disease.Multifunctional properties of RANKL/RANK in cell differentiation, proliferation and metastasis.Osteoprotegerin: A novel biomarker for inflammatory bowel disease and gastrointestinal carcinoma.Silicate modulates the cross-talk between osteoblasts (SaOS-2) and osteoclasts (RAW 264.7 cells): inhibition of osteoclast growth and differentiation.The clinical significance of OPG/sRANKL ratio in thalassemia patients suffering from osteopenia or osteoporosis in Egyptian patients.Receptor activator of nuclear factor κB ligand/osteoprotegerin axis and vascular calcifications in patients with chronic kidney disease.Bacterial Infections and Osteoclastogenesis Regulators in Men and Women with Cholesteatoma.Osteoprotegerin exposure at different stages of osteoclastogenesis differentially affects osteoclast formation and function.miRNA-340 inhibits osteoclast differentiation via repression of MITFAmlodipine and atorvastatin improved hypertensive cardiac hypertrophy through regulation of receptor activator of nuclear factor kappa B ligand/receptor activator of nuclear factor kappa B/osteoprotegerin system in spontaneous hypertension ratsFactor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival.Mechanistic study of the proangiogenic effect of osteoprotegerin.Immunohistochemical, tomographic, and histological study on onlay bone graft remodeling. Part III: allografts.cDNA cloning and characterization of a new member of the tumor necrosis factor receptor family gene from scallop, Chlamys farreri.Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties.
P2860
Q21131222-083065CC-C29C-409B-9BBE-F971D8F322F7Q24626094-31C51B07-4BC9-446F-9550-7ABE6EFCAED5Q26747442-E9DA406D-1E81-4580-9501-734B4A839A9DQ26863493-82E7C26F-74AA-4B9F-9EE6-8569189D6846Q31056800-CA807F2A-CF34-4587-96BD-796245803E65Q33891868-0AFBC283-79EE-44AC-B912-E68D7D12BFA3Q34444023-E958DFF2-5689-428F-BEF3-8CAF43082485Q34545263-7AA60341-9FAC-4596-B875-DB790A916135Q34950497-F4CD519C-ADB5-458B-B81C-1CE6463C3716Q35008981-0F49E478-AE18-4992-8264-4E1E59DE17D8Q35740351-8A636006-14DD-4348-85E0-8AF23C96FA5FQ35832019-1605B89E-8B33-406B-96DE-AC218BE5D007Q36034275-E697CE01-64A7-494F-B72D-166624AFBE4DQ36082922-75181E8D-7738-4D34-81E0-8786887D4263Q36203010-F27A3F99-0D9D-4BBC-B12C-B1C24021BA21Q36994140-03828E68-BF81-451B-8964-3D300748DD01Q37099010-EACA6B08-B157-423F-A4C7-03E5B94A9070Q37109337-A12C5750-41F2-480D-8A66-5C833F0D7A5BQ37126218-3BA491C8-1D90-4D18-9C7F-D6110F99E3E1Q37140665-5C461A6F-4919-41E9-B824-E0DA4394C4E9Q37409192-BDC4E236-54A5-4940-B698-9AA62502CD39Q37416211-D00E471C-616C-48FD-8140-BF1DA218E49AQ37694632-5EA9B2A7-84B3-4499-AA80-6F2428ED6443Q37746738-FC642237-78F3-4474-A035-ECA1A4EE00AFQ38009712-5860CFAD-2042-48E7-AF6F-C5048B782641Q38056541-C66FE682-C642-437A-8225-3FDB1A72E96DQ38155200-AA955514-CCBA-4583-A9EA-F3D1C0148856Q38741874-C7426F69-B50C-4DD9-AB29-88D57F652851Q39344647-1A76C72E-5BFF-42D7-B932-B6869E130BA9Q39423481-6D434ACC-1BC2-4CF3-ABDD-9E50568A7D62Q40084826-0654F7A9-BC71-436D-B787-AB87E42C0C79Q40903659-34DA731B-830C-4EE4-B1B2-FF36D526D069Q41184194-8AF3CCE5-46BF-4440-B7B7-117C16446D68Q42334830-E105D346-D182-43F9-9F62-60788A28FEB0Q42413757-5C0983A3-5908-4098-AADB-E9EB594C5294Q42948793-4B3594CF-7E6B-47DA-9615-E9D65AD5E3CEQ43938558-61FE07FA-0CFB-4BF4-94DB-3DD7D11D3FC6Q47405304-DBDA7258-9766-4462-B20C-3414657ECE3FQ48061286-095F6FAD-D69A-4DA6-8132-597788470A09Q54391573-86DEDEA7-F389-4E95-AB8E-F4DB22543D78
P2860
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
@ast
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
@en
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
@nl
type
label
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
@ast
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
@en
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
@nl
prefLabel
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
@ast
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
@en
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
@nl
P2093
P3181
P1476
RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
@en
P2093
F Lamoureux
M Baud'huin
P2888
P304
P3181
P356
10.1007/S00018-007-7104-0
P407
P577
2007-09-01T00:00:00Z